Wyndham H. Wilson

Wyndham H. Wilson's AcademicInfluence.com Rankings

Wyndham H. Wilson

Philosophy

#6748

World Rank

#9843

Historical Rank

Logic

#3870

World Rank

#5093

Historical Rank

philosophy Degrees

Wyndham H. Wilson

Biology

#9147

World Rank

#12317

Historical Rank

Immunology

#543

World Rank

#561

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Wyndham H. Wilson's Degrees

Masters Medicine University of Pennsylvania
PhD Immunology University of Pennsylvania

Why Is Wyndham H. Wilson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wyndham H. Wilson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling (2000) (9767)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. (2002) (2370)
Stromal gene signatures in large-B-cell lymphomas. (2008) (1611)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma (2010) (1436)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. (2004) (1410)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. (2012) (1306)
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia (2001) (1215)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. (2010) (1174)
Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma (2018) (1081)
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma (2003) (1074)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. (2003) (948)
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. (2003) (882)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma (2015) (879)
Molecular diagnosis of Burkitt's lymphoma. (2006) (871)
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. (2011) (789)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics (2012) (766)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. (2010) (679)
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. (2009) (531)
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. (2001) (504)
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma (2013) (472)
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. (2001) (464)
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. (2013) (428)
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. (2000) (425)
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. (2005) (400)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. (2020) (373)
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. (2014) (363)
Diffuse large B-cell lymphoma—treatment approaches in the molecular era (2014) (358)
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. (2003) (346)
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. (2017) (341)
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. (2005) (335)
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. (2005) (319)
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. (2015) (317)
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor (2009) (314)
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. (2002) (294)
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. (2008) (286)
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. (2012) (283)
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 (2020) (276)
Low-intensity therapy in adults with Burkitt's lymphoma. (2013) (272)
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. (2005) (263)
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. (2019) (258)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. (2007) (243)
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. (1993) (240)
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. (2012) (238)
Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. (1997) (238)
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. (2018) (235)
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. (2011) (233)
A Multiprotein Supercomplex Controlling Oncogenic Signaling in Lymphoma (2018) (229)
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. (1994) (225)
Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia (2008) (221)
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) (2017) (207)
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. (1996) (206)
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. (2009) (203)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. (2019) (198)
Treatment of HIV-associated Kaposi's sarcoma with paclitaxel (1995) (190)
Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. (2009) (188)
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. (2013) (180)
The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study (2012) (175)
The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. (1997) (171)
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. (2010) (170)
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype (2012) (169)
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. (2006) (169)
Responses in refractory hairy cell leukemia to a recombinant immunotoxin. (1999) (167)
Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. (1998) (165)
Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients (1998) (165)
The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. (2022) (165)
Mycosis fungoides and Sézary syndrome (2008) (157)
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy (2007) (156)
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia (2018) (156)
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. (1998) (155)
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. (2004) (150)
High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction (1993) (149)
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. (2013) (147)
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. (2010) (143)
Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease (2012) (142)
How I treat HIV-associated lymphoma. (2012) (140)
NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. (2011) (139)
Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. (1999) (136)
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. (2012) (131)
Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. (2019) (120)
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. (2000) (120)
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. (2016) (120)
Cutaneous Lymphomatoid Granulomatosis: Correlation of Clinical and Biologic Features (2001) (119)
Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma (2011) (118)
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. (2005) (116)
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. (1995) (116)
Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations (2011) (113)
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. (2018) (113)
Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications (2007) (112)
CNS involvement in primary mediastinal large B-cell lymphoma. (1999) (108)
Reversal of multidrug resistance. (1994) (107)
Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. (1997) (105)
Circulating serum free light chains as predictive markers of AIDS-related lymphoma. (2010) (103)
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma (2005) (102)
Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303 (2016) (101)
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. (2011) (99)
Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? (2015) (99)
Non-Hodgkin's Lymphoma in Job's Syndrome: A Case Report and Literature Review (2004) (97)
Lymphomatoid Granulomatosis—A Single Institute Experience: Pathologic Findings and Clinical Correlations (2015) (97)
Recombinant immunotoxins for treating cancer. (2004) (96)
Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. (2002) (93)
A prospective study of mediastinal gray-zone lymphoma. (2014) (93)
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1 (2011) (92)
Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. (2016) (91)
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia (2009) (90)
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy (2009) (89)
The pharmacokinetics of rituximab following an intravitreal injection. (2006) (88)
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. (1995) (88)
Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma (2011) (83)
Cardiac involvement with lymphoma: a review of the literature. (2008) (82)
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. (1994) (82)
Role of the tumor microenvironment in mature B-cell lymphoid malignancies (2016) (80)
Burkitt's Lymphoma: Molecular Pathogenesis and Treatment (2000) (78)
Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. (2005) (75)
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973–2003 in Sweden (2009) (75)
HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. (2001) (75)
EBV-associated lymphomas in adults. (2012) (75)
Targeting malignant B cells with an immunotoxin against ROR1 (2012) (74)
Flow Cytometric Immunophenotyping of Cerebrospinal Fluid (2008) (73)
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA (2021) (72)
A novel role for IL-22R1 as a driver of inflammation. (2011) (72)
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. (2015) (71)
Viral, immunologic, and clinical features of primary effusion lymphoma. (2019) (70)
Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma (2014) (70)
The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. (2002) (68)
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. (2021) (68)
Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma (2014) (68)
Cyclin D 1 – negative mantle cell lymphoma : a clinicopathologic study based on gene expression profiling (2005) (67)
Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. (2016) (65)
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. (1992) (64)
Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. (1998) (64)
Lymphomatoid Granulomatosis and Other Epstein-Barr Virus Associated Lymphoproliferative Processes (2012) (63)
Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia (2013) (62)
Rituximab-associated neutropenia. (2010) (61)
Nodal Involvement by Cutaneous CD30-positive T-cell Lymphoma Mimicking Classical Hodgkin Lymphoma (2012) (58)
Pathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment (2019) (58)
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. (2016) (57)
The landscape of new drugs in lymphoma (2017) (57)
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. (2018) (57)
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. (2020) (56)
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma (2007) (55)
Mental neuropathy (numb chin syndrome). A harbinger of tumor progression or relapse (1992) (55)
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making (2018) (54)
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. (1995) (54)
Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious (2006) (50)
Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. (2004) (50)
Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia (2013) (50)
Pathobiology and Treatment of Lymphomatoid Granulomatosis; A Rare EBV-Driven Disorder. (2020) (50)
Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial. (2020) (50)
Update on Burkitt Lymphoma. (2016) (50)
Blood levels of organochlorines before and after chemotherapy among non-Hodgkin's lymphoma patients. (2000) (48)
Treatment strategies for aggressive lymphomas: what works? (2013) (47)
Primary Mediastinal Large B-Cell Lymphoma, Classic Hodgkin Lymphoma Presenting in the Mediastinum, and Mediastinal Gray Zone Lymphoma: What is the Oncologist To Do? (2011) (47)
Flow cytometric immunophenotypic profiles of mature gamma delta T‐cell malignancies involving peripheral blood and bone marrow (2005) (46)
Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity (2015) (46)
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. (1997) (45)
Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large B-Cell Lymphoma? (2012) (45)
High-Dose Continuous Infusion β-Lactam Antibiotics for the Treatment of Resistant Pseudomonas Aeruginosa Infections in Immunocompromised Patients (2010) (41)
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. (2020) (41)
International Central Nervous System and Ocular Lymphoma Workshop: Recommendations for the Future (2006) (40)
Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype (2014) (40)
T-cell lymphoma. (2013) (39)
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. (2003) (38)
PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. (2017) (38)
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. (2017) (38)
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm. (2000) (37)
A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies (2008) (36)
Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency. (2015) (36)
A new prognostic score for AIDS-related lymphomas in the rituximab-era (2014) (36)
Clinical Reversal of Multidrug Resistance (1996) (35)
microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics (2013) (35)
Novel disease targets and management approaches for diffuse large B-cell lymphoma (2010) (35)
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. (2000) (35)
Chemotherapy sensitization by rituximab: experimental and clinical evidence. (2000) (35)
Di erent types of di use large b-cell lymphoma identi ed by gene expression pro ling (2000) (34)
Reversal of multidrug resistance. (1991) (33)
The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL (2011) (32)
Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas. (1998) (31)
Neutropenia associated with rituximab therapy (2011) (31)
Acquired immunodeficiency syndrome—related malignancies in the era of highly active antiretroviral therapy (2006) (30)
Infection of Mesothelial Cells with Human Herpes Virus 8 in Human Immunodeficiency Virus–Infected Patients with Kaposi's Sarcoma, Castleman's Disease, and Recurrent Pleural Effusions (2003) (30)
Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma (2015) (29)
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. (2005) (29)
Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. (1997) (28)
Lymphomatoid Granulomatosis (2012) (28)
B-Cell Lymphoma in a Patient with Complete Interferon Gamma Receptor 1 Deficiency (2013) (28)
FDG-PET lymphoma demonstration project invitational workshop. (2007) (27)
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Refractory or Relapsed Lymphoid Malignancies. (2007) (27)
Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients. (2006) (26)
Focus on lymphomas. (2002) (26)
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma (2013) (26)
Fluorodeoxyglucose positron emission tomography (FDG‐PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS) (2006) (26)
The role of MDR-1 in refractory lymphoma. (1997) (26)
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop (2011) (26)
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. (2010) (26)
A characteristic eruption associated with ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant interleukin-1 alpha. (1996) (25)
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia (2011) (25)
Reevaluating the Accelerated Approval Process for Oncology Drugs (2013) (25)
Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study (2008) (25)
Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. (2001) (24)
Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. (2000) (24)
Phase I/II study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma. (2004) (24)
ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). (2016) (23)
Nodal and Extranodal Plasmacytomas Expressing Immunoglobulin A: An Indolent Lymphoproliferative Disorder With a Low Risk of Clinical Progression (2010) (23)
The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma (2010) (22)
Relationship of p 53 , bcl-2 , and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin ’ s Lymphomas (1997) (22)
Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma (2016) (22)
Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation (2009) (22)
Appropriate management of molecular subtypes of diffuse large B-cell lymphoma. (2014) (22)
Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier (2017) (22)
Diffuse large B cell lymphoma: molecular targeted therapy (2012) (22)
Drug resistance in diffuse large B-cell lymphoma. (2006) (22)
Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies (2004) (22)
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia (2011) (21)
Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study (2020) (21)
Coexisting and Clonally Identical Classic Hodgkin Lymphoma and Nodular Lymphocyte Predominant Hodgkin Lymphoma (2011) (21)
CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How? (2021) (21)
Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy. (2007) (21)
A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) (2018) (21)
Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells. (2008) (20)
Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor (2008) (20)
Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome Is Significantly Improved by the Addition of Rituximab to Dose Adjusted (DA)-EPOCH and Overcomes the Need for Radiation. (2005) (20)
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies (2014) (20)
Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay (1997) (20)
Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia (2005) (19)
Prolonged half‐life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction (2011) (18)
The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15‐ICML workshop on ctDNA (2019) (18)
Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome. (2006) (17)
Immune Characteristics Associated with Lymphomatoid Granulomatosis and Outcome Following Treatment with Interferon-Alpha (2010) (17)
Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. (2022) (17)
Central nervous system involvement in AIDS‐related lymphomas (2016) (17)
Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. (1997) (17)
Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. (2002) (17)
Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy (2013) (17)
Fluorodeoxyglucose positron emission tomography in the presence of cardiac metastases. (2003) (16)
Albumin enhanced morphometric image analysis in CLL (2004) (16)
Drug resistance in adult lymphomas. (1994) (16)
Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy (2019) (16)
Angioimmunoblastic T-cell lymphoma: Immune modulation as a therapeutic strategy (2007) (16)
Lymphomatoid granulomatosis with involvement of the hard palate: a case report. (2008) (16)
Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies. (2009) (16)
Dose-Adjusted EPOCH Chemotherapy (CT) in Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma (HIV-NHL): Preliminary Report of Efficacy, Immune Reconstitution, and HIV Control Following Therapy. (1999) (16)
Clinical reversal of multidrug resistance. (1996) (16)
Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R (2015) (16)
Novel agents for B-cell non-Hodgkin lymphoma: science and the promise. (2010) (16)
Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma (2018) (16)
A Pilot Study of the Value of 18F-Fluoro-Deoxy-Thymidine PET/CT in Predicting Viable Lymphoma in Residual 18F-FDG Avid Masses After Completion of Therapy (2014) (16)
A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). (2014) (15)
A Pilot Trial of Campath-1H and Dose-Adjusted EPOCH in CD52-Expressing Aggressive T-Cell Malignancies. (2005) (15)
Decitabine in older adults with acute myeloid leukemia: why was the dream broken? (2013) (15)
Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma. (2020) (15)
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma (2015) (15)
The case for rituximab in AIDS-related lymphoma. (2006) (15)
Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma (2020) (15)
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma (2021) (14)
Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL). (2009) (14)
Aggressive Natural Killer Cell Leukemia/Lymphoma: Case Report, use of Telesynergy™ and Review of the Literature (2004) (14)
Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL). (2006) (14)
Bcl‐2 level as a biomarker for 13q14 deletion in CLL (2013) (13)
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. (2012) (13)
Reduction in platelet counts as a mechanistic biomarker and guide for adaptive dose-escalation in phase I studies of the Bcl-2 family inhibitor ABT-263 (2008) (13)
Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R (2017) (13)
Liquid biopsy in non‐Hodgkin's lymphoma (2019) (13)
RISK‐ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF a MULTICENTER PROSPECTIVE PHASE II STUDY OF DA‐EPOCH‐R (2017) (13)
Efficacy and toxicity of dose-adjusted EPOCH-rituximab in adults with newly diagnosed Burkitt lymphoma (2007) (13)
MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R (2018) (13)
Utilization of polymerase chain reaction on archival cytologic material: a comparison with fresh material with special emphasis on cerebrospinal fluids (2004) (13)
Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma. (2010) (13)
Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant (ABMT) with neoR-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer. (1993) (12)
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia (2008) (12)
Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia. (2009) (12)
A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin’s Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy. (2006) (12)
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. (2021) (12)
Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis (2020) (12)
Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work). (2004) (12)
DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation (2017) (11)
Gene expression profiling of lymphomas (2001) (11)
Circulating Tumor DNA in Lymphoma: Principles and Future Directions. (2021) (11)
The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma (2015) (11)
Bortezomib + DA-EPOCH-R Induction Therapy Followed by Maintenance Bortezomib Versus Observation in Newly Diagnosed Mantle Cell Lymphoma (2012) (11)
A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells (2010) (11)
Update on the pathogenesis, diagnosis, and therapy of AIDs-related lymphoma (2003) (11)
Methodological comparison of two anti‐ZAP‐70 antibodies (2011) (11)
The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. (2002) (11)
Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL). (2004) (11)
Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium (2013) (10)
Improved ZAP‐70 assay using two clones, multiple methods of analysis and clinical correlation (2011) (10)
ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study (2018) (10)
Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies. (2008) (10)
BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? (2007) (10)
Implications of the shifting pathobiology of AIDS-related lymphoma. (2013) (10)
Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial (2019) (10)
Monitoring of Circulating Tumor DNA As Minimal Residual Disease in Diffuse Large B-Cell Lymphoma (2014) (10)
Biology and management of rare primary extranodal T-cell lymphomas. (2010) (9)
Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma (2014) (9)
Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes (2017) (9)
Reversal of multidrug resistance. (1994) (9)
Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas (2016) (9)
Gray Zone Lymphomas: Clinical and Histological Characteristics and Treatment with Dose-Adjusted-EPOCH-R (2008) (9)
Magnesium Restores Activity to Peripheral Blood Cells in a Patient With Functionally Impaired Interleukin-2-Inducible T Cell Kinase (2019) (9)
Dose-Adjusted EPOCH-Rituximab Is Highly Effective in the GCB and ABC Subtypes of Untreated Diffuse Large B-Cell Lymphoma. (2004) (9)
Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia. (2010) (9)
Differential Role of BCL2 in Molecular Subtypes of Diffuse Large B-cell Lymphoma (2011) (9)
A multiprotein supercomplex controlling oncogenic signalling in lymphoma (2018) (9)
HIV-associated non-Hodgkin’s lymphoma (1997) (8)
Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial (2019) (8)
DA-EPOCH Chemotherapy Is Highly Effective in ALK-Positive and ALK-Negative ALCL: Results of a Prospective Study of PTCL Subtypes in Adults (2011) (8)
Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia (2013) (8)
DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers. (2006) (8)
Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). (2016) (8)
Development of Hepatic Steatosis After Chemotherapy for Non‐Hodgkin Lymphoma (2018) (8)
Refining the treatment of follicular lymphoma (2008) (8)
A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results (2010) (8)
Ongoing phase I studies of ABT-263: Mitigating Bcl-XL induced thrombocytopenia with lead-in and continuous dosing. (2009) (8)
Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA. (2018) (8)
Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. (2009) (7)
Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (2013) (7)
Combined normal donor and CLL: Single tube ZAP‐70 analysis (2012) (7)
Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma (2018) (7)
Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103 (2005) (7)
Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis (2018) (7)
Long-Term Outcome of AIDS-Related Lymphoma Treated with Abbreviated Cycles of EPOCH-RR: A Prospective Study of 40 Patients (2008) (7)
Circulating tumor DNA to predict timing of relapse in mantle cell lymphoma. (2018) (7)
Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas (2019) (6)
2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia (2007) (6)
Safety, Pharmacokinetics, Pharmacodynamics, and Activity of Navitoclax, a Targeted High Affinity Inhibitor of BCL-2, in Lymphoid Malignancies (2011) (6)
Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study (2016) (6)
Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma (2020) (6)
The Role of the Microenvironment for CLL Proliferation and Survival: Gene Expression Profiling of Leukemic Cells Derived from Blood, Bone Marrow and Lymph Nodes Reveals the B-Cell Receptor and NF κB as Dominant Signaling Pathways (2008) (6)
DA-EPOCH-R in Primary Mediastinal B-Cell Lymphoma; Analysis of End of Therapy FDG-PET and Outcome (2016) (6)
Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma (2021) (6)
Burkitt's Lymphoma. (2022) (5)
Mantle cell lymphoma: Report of the 2009 Mantle Cell Lymphoma Consortium Workshop (2010) (5)
Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study. (2018) (5)
Targeting HLA-DR (2009) (5)
A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes (2012) (5)
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas (2018) (5)
Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL (2015) (5)
Primary intraocular lymphoma: Current and future perspectives (2006) (5)
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma (2021) (5)
Progress in Chronic Lymphocytic Leukemia with Targeted Therapy. (2016) (5)
Next-generation sequencing–based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL (2021) (5)
Differential Gene Expression in CLL Cells from Bone Marrow and Peripheral Blood Suggests a Role of Bone Marrow Stroma in Leukemic Cell Proliferation. (2005) (5)
Identification of clinically distinct types of diffuse large B-cell lymphoma based on gene expressio (2000) (5)
Recent National Cancer Institute lymphoma trials of etoposide-containing combination chemotherapy. (1992) (5)
Radiofrequency ablation of lymphoma. (2005) (5)
Circulating Tumor DNA Is a Reliable Measure of Tumor Burden at Diagnosis of Diffuse Large B Cell Lymphoma: An International Reproducibility Study (2017) (5)
Emerging therapeutic paradigms to target the dysregulated JAK/ STAT pathways in hematological malignancies (2015) (5)
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma (2022) (5)
Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Clinicopathologic Study of 340 Cases from the International T-Cell Lymphoma Project. (2006) (4)
Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas (2006) (4)
Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas (2021) (4)
PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (2019) (4)
Potent Single Agent Activity and Tumor Selectivity of Bortezomib in Mantle Cell Lymphoma: First Impressions from a Randomized Phase II Study of EPOCH-Rituximab-Bortezomib in Untreated Mantle Cell Lymphoma. (2005) (4)
High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome (2015) (4)
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase III clinical trial of R‐CHOP ± ibrutinib (2021) (4)
Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma. (2004) (4)
Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma Lymphoma/Leukemia Molecular Profiling (2007) (4)
DOSE‐ADJUSTED EPOCH CHEMOTHERAPY (CT) WITH SUSPENSION OF ANTIRETROVIRAL THERAPY (ART) FOR HIV‐ASSOCIATED NON‐HODGKIN'S LYMPHOMA (HIV‐NHL): ABSTRACT S16 (2000) (4)
Therapy in primary mediastinal B-cell lymphoma. (2013) (4)
Persistent non-neoplastic gammadelta-T cells in cerebrospinal fluid of a patient with hepatosplenic (gammadelta) T cell lymphoma: a case report with 6 years of flow cytometry follow-up. (2010) (4)
Eleven-Year Follow-up of Idiotype Vaccine and DA-EPOCH-Rituximab in Untreated Mantle Cell Lymphoma: Correlation of Survival with Idiotype Immune Response (2011) (4)
NRF2 at the Interface of Oxidative and Endoplasmic Reticulum Stress Pathways Is a Critical Integrator of Bortezomib Response in Mantle Cell Lymphoma in Vitro and In Vivo. (2009) (4)
Comparison of Circulating Tumor DNA Recovery from Plasma and Serum (2017) (4)
Comparative Study of Circulating Tumor DNA and Computerized Tomography Monitoring in Untreated Diffuse Large B-Cell Lymphoma (2015) (4)
A Multi-scale, Multiomic Atlas of Human Normal and Follicular Lymphoma Lymph Nodes (2022) (4)
Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma (2020) (4)
CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage (2021) (3)
Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia (2007) (3)
End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma (2017) (3)
Comparative Gene Expression Profiling of Leukemia Cells in Peripheral Blood and Tissue Compartments Reveals a Prominent Role of the Microenvironment for CLL Cell Proliferation. (2009) (3)
Pharmacokinetics (pk) and tolerance of doxorubicin (dox) and etoposide (etop) during treatment of aggressive B-cell lymphomas indicate doses need not be routinely reduced for hepatic dysfunction (2005) (3)
Infusional chemotherapy for non-Hodgkin's lymphoma. (1997) (3)
Extraoular muscle palsies in subcutaneous panniculitis-like T-cell lymphoma. (2003) (3)
Study On The Fertility Status Of Females With Primary Mediastinal B-Cell Lymphoma Following Treatment With Dose-Adjusted EPOCH-Rituximab (2013) (3)
Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia. (2009) (3)
Gene Expression Profiling Reveals The Lymph Node Microenvironment As a Niche For BCR Engagement, NFκB Pathway Activation, and Tumor Proliferation In Mantle Cell Lymphoma (2013) (3)
B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor (2011) (3)
A Prospective Study of Clonal Evolution in Follicular Lymphoma: Circulating Tumor DNA Correlates with Overall Tumor Burden and Fluctuates over Time without Therapy (2021) (3)
The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma (2007) (3)
Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens. (2005) (3)
Official Title: PILLAR-2 trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of RAD001 Adjuvant Therapy in Poor-Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rit (2010) (3)
Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis (2019) (3)
What is the standard of care for primary mediastinal b‐cell lymphoma; R‐CHOP or DA‐EPOCH‐R? (2019) (3)
DNA Sequencing-Based Monitoring Of Serum Predicts Clinical Relapse Before CT Imaging in Diffuse Large B-Cell Lymphoma (2013) (3)
HIV VIRAL BURDEN (VB) DURING EPOCH CHEMOTHERAPY (CT) FOR HIV-RELATED LYMPHOMAS: 104 (1997) (3)
Phased variants improve DLBCL minimal residual disease detection at the end of therapy. (2021) (2)
Diffuse Large B-Cell Lymphoma Subgroups Have Distinct Genetic Profiles that Influence Tumor Biology and Improve Gene Expression-Based Survival Prediction for the Lymphoma/Leukemia Molecular Profiling Project (2005) (2)
End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al. (2018) (2)
Genetics of Diffuse Large B-Cell Lymphoma. (2018) (2)
The Addition of Rituximab to Dose-Adjusted EPOCH with HAART Suspension Is Highly Effective and Tolerable in AIDS-Related Lymphoma (ARL) and Allows the Delivery of Abbreviated Chemotherapy. (2005) (2)
Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant (2019) (2)
Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis (2021) (2)
Clinical aspects and treatment of angioimmunoblastic T cell lymphoma (AILD) (1999) (2)
Loss of CD20 Expression and Exhaustion of Effector Cells Limit ADCC in CLL Patients Treated with Rituximab. (2009) (2)
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma (2019) (2)
High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma (2011) (2)
Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib (2021) (2)
PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B‐CELL LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS (2019) (2)
Non-coding NFKBIZ 3′ UTR mutations promote cell growth and resistance to targeted therapeutics in diffuse large B-cell lymphoma (2021) (2)
Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL). (2012) (2)
Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study (2008) (2)
distinct gene expression profile with unmutated immunoglobulin genes , inferior clinical outcome , and ZAP-70 expression identifies a chronic lymphocytic leukemia subtype (2003) (2)
FDG-PET as a Marker of tumor proliferation Compared to Gene-Expression Proliferation Scores, MIB1%, and LDH In Untreated Mantle Cell Lymphoma (MCL) (2010) (2)
Paclitaxel administration using portable infusion pumps. (1993) (2)
106 – Non-Hodgkin Lymphoma (2014) (2)
subtypes of diffuse large B-cell lymphoma Differential efficacy of bortezomib plus chemotherapy within molecular (2013) (2)
A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up (2018) (2)
Reply to J. Wang et al. (2019) (2)
Chapter 82 – Diagnosis and Treatment of Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma (2018) (2)
Uncommon Presentations of Malignancies CASE 1. EXTRAOCULAR MUSCLE PALSIES IN SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA (2003) (2)
Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment (2022) (2)
Interim Phase I Results of Recombinant Immunotoxin HA22 in Patients with Hairy Cell and Chronic Lymphocytic Leukemias (2008) (2)
Pharmacokinetics (pk) and tolerance of infusional vincristine (vcr) for aggressive lymphomas indicate dose reductions for excretory organ dysfunction are not necessary (2008) (2)
Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma (2018) (2)
Studies of drug resistance in malignant lymphoma (1993) (2)
disease: a 28-year experience in the United States Characterization and treatment of chronic active Epstein-Barr virus (2011) (1)
Cracking the diverse biologic code of diffuse large B-cell lymphoma. (2015) (1)
POLATUZUMAB VEDOTIN WITH BENDAMUSTINE AND RITUXIMAB FOR RELAPSED/REFRACTORY HIGH‐GRADE B‐CELL LYMPHOMA: THE UK EXPERIENCE (2021) (1)
CNS involvement in patients with AIDS-related lymphomas. (2014) (1)
Bortezomib plus DA-EPOCH-rituximab followed by bortezomib maintenance versus observation in previously untreated mantle cell lymphoma (MCL). (2011) (1)
High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma (2011) (1)
Methylation Profiling of Mediastinal Gray Zone Lymphoma Reveals a Distinctive Signature with Elements Shared by Classical Hodgkin's Lymphoma and Mediastinal Large B-Cell Lymphoma (2010) (1)
Long term follow-up of BL22 in cladribine-resistant hairy cell leukemia (2004) (1)
Pharmacokinetics and Tolerability of Etoposide in Newly Diagnosed Lymphoma Patients with Hepatic Impairment (2014) (1)
Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma (2010) (1)
follow-up in a unique case series mimicking intestinal lymphoma: clinicopathologic features and NK-cell enteropathy: a benign NK-cell lymphoproliferative disease (2011) (1)
Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial. (2023) (1)
Treatment and biology of lymphomatoid granulomatosis (2007) (1)
Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST). (2006) (1)
Pharmacokinetics and tolerability of doxorubicin in newly diagnosed lymphoma patients with hepatic impairment. (2014) (1)
The diversity of p53/p2l transactivation phenotype of p53 signaling pathway and their relationship to TP53 gene mutation and clinical outcome in diffuse large B-Cell lymphoma (DLBCL) (2007) (1)
BK viral infections in patients treated with alemtuzumab (2007) (1)
Rituximab Induces an Interferon Gene Expression Signature in Patients with CLL. (2006) (1)
The outcome of ALK positive and ALK negative anaplastic large cell lymphoma (ALCL) following DA-EPOCH. (2015) (1)
Advances in the Treatment of Primary CNS Lymphoma: FR‐S26‐NHL‐160 (2018) (1)
Phase I trial of recombinant immunotoxin anti-Tac -PE38 in patients with hematologic malignancies (1998) (1)
KEY GENETIC AND MOLECULAR ABERRATIONS IDENTIFIED IN BOTH ADULT AND EBV‐POSITIVE BURKITT LYMPHOMA PATIENTS (2021) (1)
Clinical Impact of Somatic Copy Number Alterations in Circulating Tumor DNA from Diverse Lymphoma Subtypes (2017) (1)
Burkitt Lymphoma Genome Sequencing Project (BLGSP): Integrative Genomic and Transcriptomic Characterization of Burkitt Lymphoma (2017) (1)
Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox. (2012) (1)
Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma (2008) (1)
R-verapamil reverses drug resistance in some relapsed lymphoma patients: 165 (1994) (1)
A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (2012) (1)
Rituximab Is Associated with Prolonged Immunoglobulin Deficiency In Newly Diagnosed Patients with Aggressive B-Cell Lymphoma Receiving Immunochemotherapy (2010) (1)
Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma (2020) (1)
A Phase I/II Study of a Hybrid Schedule of Flavopiridol in Relapsed/Refractory Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma (2010) (1)
Immunotherapy and Chemotherapy Can Result in Long-Term Survival for Patients with Recurrent or Progressive Non-Hodgkin’s Lymphoma after Reduced-Intensity Allogeneic Stem Cell Transplantation. (2004) (1)
Plasma and cerebrospinal fluid pharmacokinetics of doxil after intravenous administration in adults with primary CNS lymphoma. (2017) (1)
A Prospective Multicenter Phase 2 Study of Dose-Adjusted-EPOCH-R in Untreated MYC-Rearranged Aggressive B-cell Lymphoma (2019) (1)
Hemophagocytosis and coagulopathy associated with cutaneous γ‐δ T‐cell lymphoma (2004) (0)
Human Cancer Biology microRNA Expression Pro fi les Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics (2013) (0)
Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma (2016) (0)
‘ ‘ focus on . . . ’ ’ session : profiling and prognosis (2008) (0)
Chromosomal aberrations in gray zone lymphomas (2011) (0)
Antitumor Activity Of Recombinant Inumunotoxin Anti-tac(fv)-pe38 (lmb-2) In Patients With Hematologic Malignancies (1999) (0)
Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis (2023) (0)
Reply to M. Hertzberg et al. (2020) (0)
Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL). (2006) (0)
ZAP-70 Expression Is Associated with Increased Migration to SDF-1 in Chronic Lymphocytic Leukemia. (2006) (0)
A Multi-Institutional Biomarker Study of Large B-cell Lymphomas in FDG PET/CT - Experiences within the Oncology Biomarker Qualification Initiative (OBQI) (2016) (0)
Methotrexate alters hematopoietic recovery and engraftment kinetics when added to cyclosporine for acute GVHD prophylaxis after reduced-intensity stem cell transplantation (2005) (0)
A pooled analysis of 1,144 patients with HIV-associated lymphoma: Assessment of lymphoma-, HIV-, and treatment-specific factors on clinical outcomes. (2012) (0)
PL3-5 A novel role of IL-22R1 as a possible driver of inflammation in ALK+ anaplastic large cell lymphoma (2010) (0)
Chapter 4 Molecular Diagnosis of Burkitt lymphoma (2019) (0)
Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases (2014) (0)
W1143 Colonic Distribution of Mantle Cell Lymphoma (2010) (0)
An immune-depleting strategy with antitumor activity for refractory b cell malignancy prior to nonmyeloablative allogeneic stem cell transplantation (2000) (0)
A pooled analysis of 1,546 patients with AIDS-related lymphoma (ARL): An assessment of prognostic factors by treatment era. (2013) (0)
B-Cell Lymphoma in a Patient with Complete Interferon Gamma Receptor 1 Deficiency (2013) (0)
CCR Perspectives in Drug Approval Reevaluating theAcceleratedApprovalProcess forOncology Drugs (2013) (0)
University of Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics (2012) (0)
Blood Levels of Organochlorines Before, During and After Chemotherapy Among Non-Hodgkin Lymphoma (NHL) Patients (2009) (0)
Lymphomas (2018) (0)
The diversity of p53/p21 transactivation phenotype of p53 signaling pathway and their relationship to TP53 gene mutation and clinical outcome in diffuse large B-cell lymphoma (DLBCL) (2007) (0)
P1459: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA (B-NHL), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL) (2022) (0)
Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS (2019) (0)
A missense mutation impairs ITK function in a patient with severe Epstein-Barr virus disease. (2018) (0)
HIV-associated lymphoid neoplasms (2010) (0)
Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma? (2022) (0)
Interim Results of Secondary Endpoints From a Randomized Trial of Cladribine with Early Vs Delayed Rituximab for Treatment of Early Hairy Cell Leukemia (2011) (0)
Pharmacokinetics of recombinant immunotoxin BL22 during phase II testing in chemo-resistant hairy cell leukemia (2008) (0)
Detection of MDR1 alleles and acquired mutations as tools for understanding expression of MDR1 in drug selected cell lines and human cancers: 160 (1994) (0)
induces a p 53-dependent gene expression response Fludarabine treatment of patients with chronic lymphocytic leukemia (2004) (0)
Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R (2021) (0)
Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR). (2012) (0)
Bendamustine and Rituximab for the Treatment of Multiply Relapsed Hairy Cell Leukemia (2011) (0)
Taxol for treatment of lymphoma and breast cancer and the rundown of multi-drug resistance against taxol (1993) (0)
611 Bcl-2 family protein expression in navitoclax-treated patients (pts) with lymphoid malignancies (2010) (0)
Malignancy in STAT3 Deficient Hyper IgE Syndrome (2022) (0)
Borderlands between pathological entities: composite lymphomas (2010) (0)
Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance] (2020) (0)
34 ORAL Advantages of a modified continual reassessment method (CRM) for dose finding studies: experience in ongoing phase I trials with ABT-263 (2008) (0)
Long term follow-up of BL22 in cladribine-resistant hairy cell leukemia. (2004) (0)
Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care - Authors' reply. (2019) (0)
The Effectiveness of Dual-Staining Immunohistochemistry in the Detection of Mantle Cell Lymphoma in the Bone Marrow. (2022) (0)
Molecular and Cellular Pathobiology Molecular Subsets of Mantle Cell Lymphoma De fi ned by the IGHV Mutational Status and SOX 11 Expression Have Distinct Biologic and Clinical Features (2012) (0)
Cancer Therapy : Clinical Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia (2013) (0)
5.21 ROR1-Immunotoxin as a Potential Therapeutic Agent for Certain Human B-cell Malignancies (2011) (0)
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial. (2023) (0)
Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL). (2012) (0)
Molecular Effects of Rituximab on CLL Cells In Vivo: Rapid Increase in Serum Interferon gamma, Induction of a Distinct Tumor Cell Gene Expression Signature and Loss of CD20 Expression. (2007) (0)
Rapid Clearance of Rituximab Contributes to the Continued High Incidence of Autoimmune Complications of Chemoimmunotherapy for Chronic Lymphocytic Leukemia (2010) (0)
infection of B lymphocytes and response to interferon-alpha 2b Association of lymphomatoid granulomatosis with Epstein-Barr viral (2011) (0)
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy (2022) (0)
Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology (2020) (0)
Persistent non-neoplastic gd-T cells in cerebrospinal fluid of a patient with hepatosplenic (gd) T cell lymphoma: a case report with 6 years of flow cytometry follow-up (2009) (0)
Management of heavy chain diseases: the challenges of biologic heterogeneity. (2014) (0)
gene expression profile unmutated immunoglobulin genes, inferior clinical outcome, and distinct ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with (2013) (0)
Chromosomal Translocation Chromosomal Translocation Mechanisms and Consequences of Mechanisms and Consequences of (2006) (0)
Immunoablative Chemotherapy before Reduced-Intensity Allogeneic Stem Cell Transplantation: A Strategy to Provide Disease Control and to Enhance Early Graft-Versus-Lymphoma Effects. (2004) (0)
Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms (2015) (0)
Abstract 64: Interleukin-10 Decreases HDL: A Novel Cause of Disappearing HDL Syndrome (2013) (0)
Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure (2021) (0)
Effect of Isavuconazole on Plasma and CSF Levels of Ibrutinib and Plasma Levels of Liposomal Doxorubicin Among Patients Receiving Teddi-R for CNS Lymphoma (2022) (0)
44. Burkitt Lymphoma (2014) (0)
Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy. (2009) (0)
Failure in Patients with Advanced Malignancy A Pilot Study of CTLA-4 Blockade after Cancer Vaccine (2007) (0)
Lymphoma: Burkitt's and lymphoblastic lymphomas (2007) (0)
High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R (2013) (0)
High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA. (2004) (0)
Lymphoma: Burkitt and lymphoblastic lymphoma: clinical therapy and outcome (2013) (0)
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial (2022) (0)
Transfusion medicine illustrated. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma. (2004) (0)
Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing (2018) (0)
COPY NUMBER VARIATION ANALYSIS IDENTIFIES DISTINCT GENOMIC FEATURES IN ADULT BURKITT LYMPHOMA (2021) (0)
Whole-Body Positron Emission Tomography (PET) Using 2-18Fluoro-2-Deoxy-D-Glucose (FDG) for Monitoring Lymphadenopathy in Autoimmune Lymphoproliferative Syndrome (ALPS). (2004) (0)
High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor (2008) (0)
Expanding the Precision Medicine Toolkit With Circulating Tumor DNA. (2020) (0)
New Treatment Strategies in Chronic Lymphocytic Leukemia (2004) (0)
Using [18F]FLT PET/CT to predict viable lymphoma in residual FDG avid masses following completion of therapy (2011) (0)
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease (2022) (0)
Novel Genetic Subgroups Inform on Shared Pathobiology within Adult and Pediatric Burkitt Lymphoma (2021) (0)
R-CHOP strikes again with survival benefit in follicular lymphoma (2005) (0)
FDG-PET SUV Correlates with Expression of Genes Reflecting Proliferation, Metabolism, and Oncogene Activity in Mantle Cell Lymphoma (MCL), (2011) (0)
Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens. (2006) (0)
survival in mantle cell lymphoma mRNAs that are associated with increased proliferation rate and shorter Point mutations and genomic deletions in Cyclin D1 create stable truncated (2013) (0)
ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era (2012) (0)
Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance). (2020) (0)
Elevated Interleukin-10 and “Disappearing HDL Syndrome” in Lymphoproliferative Disorders (2014) (0)
EPOCH-FR: A novel salvage regimen for patients with lymphoid malignancies being considered for reduced-intensity allogeneic hematopoietic stem cell transplantation. (2010) (0)
Immunotherapy of Lymphomatoid Granulomatosis (2022) (0)
Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas (2019) (0)
Ongoing Activation of the BCR, NFκB, and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironnment (2014) (0)
Primary Mediastinal B-Cell Lymphoma (2013) (0)
Clinical aspects and treatment options in nasal/nasal type lymphoma (angiocentric lymphoma) and lymphomatoid granulomatosis (1999) (0)
DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features (2022) (0)
172 Syk kinase activity is required for ΔNp63α-driven nuclear c-Rel accumulation associated with ΔNp63α/v-RasHA mediated carcinogenesis (2018) (0)
Early phase I results of recombinant immunotoxin HA22 in patients with B-cell leukemia (2008) (0)
Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR (2019) (0)
Phase II study of EPOCH infusional chemotherapy in relapsed or refractory Hodgkin's lymphoma (HL). A report on toxicity, efficacy and prognostic indicators of outcome. (2004) (0)
CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B‐CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Wyndham H. Wilson?

Wyndham H. Wilson is affiliated with the following schools:

George Washington University
Gyeongsang National University
Massachusetts General Hospital
University of Nebraska Medical Center
University of Pennsylvania

Wyndham H. Wilson's Academic­Influence.com Rankings

Wyndham H. Wilson's Degrees

Why Is Wyndham H. Wilson Influential?

Wyndham H. Wilson's Published Works

Published Works

What Schools Are Affiliated With Wyndham H. Wilson?

Wyndham H. Wilson's AcademicInfluence.com Rankings